日韩精品无码一区二区三区免费,在线观看欧美一区,高清国产免费观看,久久久久精品视频,免费观看国产小粉嫩喷水,久久播放无码专区

產(chǎn)品資料

Pazopanib, Free Base **

如果您對(duì)該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱: Pazopanib, Free Base **
產(chǎn)品型號(hào): LC P-6706
產(chǎn)品展商: 原裝進(jìn)口
產(chǎn)品文檔: 無相關(guān)文檔

簡(jiǎn)單介紹

Pazopanib, Free Base **


Pazopanib, Free Base **  的詳細(xì)介紹
Pazopanib, Free Base **

產(chǎn)品名稱:Pazopanib, Free Base
產(chǎn)品貨號(hào):LC  P-6706
產(chǎn)品規(guī)格:100 MG
Pazopanib is an oral, second-generation, potent and selective multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor and c-kit, key proteins responsible for tumor growth and angiogenesis.  Pazopanib showed good potency against all of the human VEGFRs and some related tyrosine receptor kinases in vitro, and demonstrated antitumor activity against renal cell carcinoma (RCC), and breast, lung, and other related cancers.  Sloan, B. and Scheinfeld, N.S.  "Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy."  Curr. Opin. Investig. Drugs 9:  1324-1335 (2008).
Preclinical evaluation has demonstrated excellent anti-tumor and anti-angiogenic activity.  A Phase II clinical trial of pazopanib in untreated or cytokine/bevacizumab pretreated renal cell carcinoma has revealed promising activity with a favorable toxicity profile.  Sonpavde, G., et al.  "Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma."  Expert Opin. Investig. Drugs 17:  253-261 (2008).
Orally administered Pazopanib has good bioavailability to the retina/choroid and strongly suppresses choroidal neovascularization (CNV) in a dose-dependent manner in mice.  Takahashi, K., et al.  "Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib."  Arch. Ophthalmol. 127:  494-499 (2009).
Pazopanib inhibits in vivo tumor cell growth in a mouse xenograft model of human multiple myeloma (MM) associated with increased MM cell apoptosis, prolonged survival, and decreased angiogenesis.  Podar, K., et al.  "The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma."  Proc. Natl. Acad. Sci. USA 103:  19478-19483 (2006).
Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 8.3 mg/mL with slight warming; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

產(chǎn)品留言
標(biāo)題
聯(lián)系人
聯(lián)系電話
內(nèi)容
驗(yàn)證碼
點(diǎn)擊換一張
注:1.可以使用快捷鍵Alt+S或Ctrl+Enter發(fā)送信息!
2.如有必要,請(qǐng)您留下您的詳細(xì)聯(lián)系方式!
使用指南 付款方式 客戶關(guān)懷 **與保密 法律幫助 服務(wù)條款 監(jiān)察中心信箱
分享到:

滬公網(wǎng)安備 31011002002623號(hào)